Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACkER trial of triple versus dual inhaled therapy in COPD with asthma features
NL-OMON28851Recruiting
- Sponsor
- General Practitioners Research Institute
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium, beclomethasone dipropionate, formoterol, glycopyrronium and long-acting beta2-agonist + long-acting muscarinic antagonist in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by General Practitioners Research Institute. Started Dec 2019; status: recruiting.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumbeclomethasone dipropionateformoterolglycopyrroniumlong-acting beta2-agonist + long-acting muscarinic antagonist
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON28851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28851.